How do Cosentyx and Humira compare in psoriasis “success rate”?
Both Cosentyx (secukinumab) and Humira (adalimumab) are used for moderate-to-severe plaque psoriasis, and pivotal trials commonly report response rates such as PASI 75 (a 75% improvement in Psoriasis Area and Severity Index). However, the exact “success rate” depends on which specific trial, dose, and time point you mean (for example, week 12 vs week 16/24).
At the moment, the provided information does not include the specific psoriasis trial response numbers for Cosentyx versus Humira, so I can’t accurately compare their success rates without fabricating figures.
Which psoriasis outcomes are usually compared (and why it changes the answer)?
Most head-to-head comparisons (or cross-trial comparisons) hinge on endpoints like:
- PASI 75, PASI 90, or PASI 100 response rates
- “Clear/almost clear” on the static Physician’s Global Assessment (sPGA)
- Time point (12 weeks, 16 weeks, 24 weeks, etc.)
- Patient characteristics (e.g., biologic-naive vs biologic-experienced populations)
Because these factors vary across studies, two papers can both say “high efficacy” while reporting different “success rates.”
Do you mean Cosentyx vs Humira head-to-head, or separate trials?
The comparison is very different depending on whether the data come from:
- a direct head-to-head trial (same design, endpoints, population), or
- separate pivotal trials (indirect comparison; can differ due to protocol and baseline severity).
If you tell me whether you want an indirect comparison across commonly cited trials or a true head-to-head comparison (and which endpoint/time point), I can format the comparison accordingly.
What I need to give a precise numbers-based comparison
Please share either:
1) the trial names (or links) you’re using for Cosentyx and Humira, or
2) the endpoint/time point you care about (for example, “PASI 75 at week 12”).
With that, I can provide a clear side-by-side comparison of the reported success rates using the figures from those sources.